HUMAN CYTOMEGALOVIRUS (HCMV) LEUKODNAEMIA CORRELATES MORE CLOSELY WITH CLINICAL SYMPTOMS THAN ANTIGENEMIA AND VIREMIA IN HEART AND HEART-LUNG TRANSPLANT RECIPIENTS WITH PRIMARY HCMV INFECTION1
Authors:
- Maurizio ZavattoniMZMaurizio Zavattoni
- Fausto BaldantiFausto Baldanti
- Antonella SarasiniASAntonella Sarasini
- Lucia ChezziLCLucia Chezzi
- Paolo GrossiPGPaolo Grossi
- M. Grazia RevelloMRM. Grazia Revello
- 1 May 1998
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 65 (10) , 1378-1385
Abstract
In the last few years, human cytomegalovirus (HCMV) viremia, pp65 antigenemia, and leuko- and plasma-DNAemia have been developed to quantitate virus in blood of immunocompromised patients with HCMV infection. However, thus far, no conclusive studies have been performed to define the correlation of each of the different assays with clinical symptoms in primary HCMV infections. This correlation was investigated in a population of 20 heart and heart-lung transplant recipients with primary HCMV infection using standardized virological methods. Median peak HCMV viremia, antigenemia, and leukoDNAemia levels were 110(0-2,000) p72-positive fibroblasts, 450 (27-2,000) pp65-positive leukocytes, and >10,000 (1,358-10,000) genome equivalents (GE) in the 14 symptomatic patients and 18 (1-130) p72-positive fibroblasts, 86.5 (5-350) pp65-positive leukocytes, and 248 (10-863) GE in the six asymptomatic patients, respectively. The difference was statistically significant for antigenemia(P=0.009) and leukoDNAemia (P<0.0001). However, on an individual basis, unlike viremia and antigenemia, all DNA peaks of the 6 asymptomatic patients were below the DNA range of the 14 symptomatic patients(1,000 GE). Follow-up confirmed these results, showing that 1,000-2,000 GE was the threshold zone for emergence of clinical symptoms. Symptoms were never observed in patients with secondary DNA peaks, except for one patient suffering from an HCMV organ localization(HCMV gastritis). LeukoDNAemia is the viral parameter of choice for monitoring of primary HCMV infections and antiviral treatment in heart and heart-lung transplant recipients. In this patient population, antigenemia-guided preemptive therapy could be replaced by leukoDNAemia-based antiviral therapy.Keywords
This publication has 27 references indexed in Scilit:
- INCIDENCE AND RISK FACTORS ASSOCIATED WITH THE DEVELOPMENT OF CYTOMEGALOVIRUS DISEASE AFTER INTESTINAL TRANSPLANTATIONTransplantation, 1995
- CLINICAL AND VIROLOGICAL MONITORING OF HUMAN CYTOMEGALOVTRUS INFECTION IN 294 HEART TRANSPLANT RECIPIENTSTransplantation, 1995
- Quantitation of human cytomegalovirus glycoprotein H gene in cells using competitive PCR and a rapid fluorescence-based detection systemJournal of Virological Methods, 1995
- Effect of foscarnet induction treatment on quantitation of human cytomegalovirus (HCMV) DNA in peripheral blood polymorphonuclear leukocytes and aqueous humor of AIDS patients with HCMV retinitis. The Italian Foscarnet Study GroupAntimicrobial Agents and Chemotherapy, 1994
- Quantification of human cytomegalovirus DNA in peripheral blood polymorphonuclear leukocytes of immunocompromised patients by the polymerase chain reactionJournal of Virological Methods, 1993
- Quantification of human cytomegalovirus DNA using the polymerase chain reactionJournal of General Virology, 1992
- Impact of Cytomegalovirus Infection on Organ Transplant RecipientsClinical Infectious Diseases, 1990
- A 6-hour microneutralization assay for human cytomegalovirus antibody by using monoclonal antibodiesSerodiagnosis and Immunotherapy in Infectious Disease, 1990
- Infections after Liver TransplantationMedicine, 1988
- The Transplanted Kidney as a Source of Cytomegalovirus InfectionNew England Journal of Medicine, 1975